Genervon Will Present at Biotech Showcase™ Mechanisms of Actions of GM604 on 30 ALS Genes

Biotech Showcase 2013

PASADENA, Calif.--()--Genervon Biopharmaceuticals, LLC, a clinical stage biopharmaceutical company focused on neurodegenerative diseases, announced today that President and CEO, Winston Ko will present at the Biotech Showcase™ 2013 Conference being held in San Francisco on Tuesday (1/08/13) 10:45AM.

Mr. Ko will provide the details of the breaking news that the Mechanism Of Actions of ALS by GM604 has been confirmed. GM604 controls 4000 genes and modulates over 30 ALS related genes at the same time through at least 8 pathways and 22 biologic processes.

GM602 and GM608 are in Phase 2 clinical trial for Ischemic Stroke and Parkinson’s disease respectively. GM604 is Phase 2 ready for Amyotrophic lateral sclerosis (ALS). Genervon is seeking pharmaceutical companies to license and help advance in phase 2 clinical trials for ALS and ten other indications.

Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About Genervon Biopharmaceuticals:

Genervon has discovered a novel endogenous embryonic stage family of 9 human Master Regulators of the Nervous System. It has obtained 46 Composition of Matter and Use patents.

GM604 also proved to be very effective in the disease modification in ALS animal model with mutant SOD1 gene. It led to improved clinical scores in SOD1 mice. Moreover, GM604 delayed the onset of ALS symptoms by 27%, extended life by 30% and delayed the median clinical score deterioration time in ALS mice by 41%.

GM604 also provided neuroprotection against soluble inflammatory factors from ALS human patients’ Cerebral Spinal Fluid (CSF) in vitro by 175%.

GM604 dramatically increased the survival life span by 500% (6 fold from 7-14 weeks to 55-65 weeks) and increased preservation of motoneurons by 160% (2.6 fold) in a Wobbler Mice Model for motoneuron diseases similar to ALS.

The discovery of endogenous embryonic stage human master regulators is changing the drug development paradigm from hitting single gene/pathway to a comprehensive and dynamic multi-factorial approach to treat the complex neuro-degenerative diseases. Genervon is at the forefront of a drug development paradigm shift that is beginning to be appreciated.

Genervon Biopharmaceuticals, LLC is an innovative clinical stage biopharmaceutical company providing breakthrough biological drugs for unmet medical needs.

Contacts

For Media & Investors:
Genervon Biopharmaceuticals, LLC
Dorothy Ko, COO
323-721-5500
dko@genervon.com
www.genervon.com

Release Summary

Genervon will present at Biotech Showcase 2013 its neuroprotective peptide GM604 regulates over 4000 genes, modulates 30 ALS genes, 8 pathways, delayed ALS disease onset by 27%, extended life by 30%.

Sharing

Contacts

For Media & Investors:
Genervon Biopharmaceuticals, LLC
Dorothy Ko, COO
323-721-5500
dko@genervon.com
www.genervon.com